by Green Griffith | Jun 7, 2021 | IP News
Summary Judgment Win in U.S. District Court Results in All Asserted Claims Being Found Invalid Clearing the Path for the Continued Marketing of Clarus’s Oral Testosterone Replacement Product JATENZO® Judge William C. Bryson granted Clarus Therapeutics’s motion for...
by Green Griffith | Sep 30, 2020 | IP News
Writing in Law360, former Federal Circuit Judge Paul Michel and renowned appellate lawyer John Battaglia ask the U.S. Supreme Court to grant certiorari to Horizon. Two prominent members of the federal bar have weighed in on the Horizon arthritis drug patent case...
by Green Griffith | Apr 16, 2019 | Firm News, IP News
Green, Griffith & Borg-Breen adds Olga Schwier to experienced IP team Green Griffith is pleased to announce the addition of Olga Schwier, Ph.D. to its Intellectual Property team as an Associate Attorney. Olga graduated with honors from the University of Chicago...
by Green Griffith | Feb 21, 2019 | IP News
TEVA prohibited from providing compensation in the form of a business transaction and a no-Authorized Generic (AG) commitment The FTC has reached settlement with TEVA Pharmaceuticals in three antitrust lawsuits addressing reverse-payment settlement agreements in...
by Green Griffith | Feb 8, 2019 | IP News
Any “Delay Caused by Applicant” Found by USPTO to Reduce PTA Should be Re-Evaluated in View of Supernus Decision. In a January 23, 2019, opinion, the Federal Circuit determined that the U.S. Patent and Trademark Office (USPTO) improperly calculates patent term...
by Green Griffith | Jan 24, 2019 | IP News
AIA did not change law pertaining to “on sale” activities. The US Supreme Court in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., determined that because Congress retained the prior “on sale” language in the AIA, it also adopted the prior judicial...
